Rhythm Pharmaceuticals, Inc. (RYTM) Stock Forecast
RYTM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 18 analysts
- Price target
- $143.94 average of analyst targets
- Upside to target
- +67.0% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-0.68
- 52-week range
- $75.82 – $117.62
RYTM analyst ratings
18 analystsNumber of analysts at each rating.
RYTM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RYTM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.74 | −$0.85 | −$0.66 | −$0.82 | +9.4% | 13 |
| Current fiscal year (2026) | −$3.04 | −$3.36 | −$2.82 | −$3.11 | +2.1% | 13 |
| Next fiscal year (2027) | −$0.63 | −$2.45 | $0.49 | −$3.04 | +79.3% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RYTM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $84.5M | $78.0M | $93.0M | +64.7% | 16 |
| Current fiscal year (2026) | $315.1M | $299.4M | $336.4M | +66.1% | 18 |
| Next fiscal year (2027) | $565.1M | $460.0M | $672.3M | +79.3% | 19 |
RYTM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RYTM revenue: reported and forecast
RYTM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.82 | −$0.75 | −$0.76 | −$0.75 | −$0.74 | −9.5% | 2 up · 1 down |
| Current fiscal year (2026) | −$3.24 | −$3.07 | −$3.10 | −$3.08 | −$3.04 | −5.9% | 2 up · 1 down |
| Next fiscal year (2027) | −$0.73 | −$0.61 | −$0.61 | −$0.53 | −$0.63 | −14.1% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RYTM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RYTM beat in 9 of 12.
What analysts expect from RYTM
18 analysts cover Rhythm Pharmaceuticals; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $143.94, 67.0% above the latest close of $86.17. Analysts expect earnings of −$3.04 per share for 2026, +2.1% from a year earlier. For 2027 the average estimate is −$0.63 per share on revenue of $565.1 million. Rhythm Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: RYTM income statement, RYTM key metrics, RYTM chart. See the RYTM stock overview for the latest quote and news.
RYTM forecast FAQ
What is Rhythm Pharmaceuticals's price target?
The average analyst price target for Rhythm Pharmaceuticals is $143.94, 67.0% above the latest close of $86.17.
Is Rhythm Pharmaceuticals a buy, hold or sell?
Of 18 analysts covering Rhythm Pharmaceuticals, 11 rate it a strong buy, 5 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Rhythm Pharmaceuticals's EPS forecast?
Analysts forecast −$3.04 per share for 2026 (range −$3.36 to −$2.82); for 2027 the estimate is −$0.63.
What is Rhythm Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $315.1 million, growth of 66.1%; for 2027 it is $565.1 million.
When does Rhythm Pharmaceuticals report earnings?
Rhythm Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $-0.68.
Does Rhythm Pharmaceuticals usually beat earnings estimates?
Rhythm Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.